Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, called XPORT-EC-042 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.